Navigation Links
DecisionQ Partners With Thomas Jefferson University to Reveal Insights for Cancer Therapy

Partnership integral piece of consortium recently awarded five-year, $6.7 million Susan G. Komen for the Cure Promise Grant

WASHINGTON, April 29 /PRNewswire/ -- Thomas Jefferson University's Kimmel Cancer Center has partnered with DecisionQ, a leader in predictive analytics and machine learning to uncover life-saving answers hidden in the center's proprietary and extensive cancer registries. DecisionQ will leverage its expertise in developing predictive algorithms to identify how patients will respond to different therapeutic options for breast and colon cancers.

The team is part of a consortium that was recently awarded a Susan G. Komen for the Cure Promise Grant of nearly $6.7 million for five years of continued breast cancer research. Promise grants support multi-disciplinary research with the greatest potential to significantly reduce breast cancer incidence and/or mortality within the next decade.

"Identification of therapy-relevant biomarkers is a crucial part of breast cancer research, as there are many different biomarkers that could predict treatment response and outcome, and serve as targets for treatment," said Hallgeir Rui, M.D., Ph.D., professor of Cancer Biology at Thomas Jefferson University. "DecisionQ's Faster AnalyticsTM will be used to further refine the team's predictive models in breast cancer, helping us to identify protein biomarker patterns that can be used to make sure patients are offered the most appropriate therapy."

Leading experts in the fields of decision analysis, statistics and machine learning have developed the technology and approach that DecisionQ applies in creating MMIA's (multi marker interpretive assays), greatly enhancing the quality of human judgment in an interactive, real-time environment at a low marginal cost.

"More than a million new cancer diagnoses are documented each year, giving researchers vast amounts of data with which to work," said Todd Radano, co-founder of DecisionQ. "Applying advances in analytics via machine learning will assist scientists in taking what is known about the disease and developing actionable insights that could ultimately save lives."

About DecisionQ Corporation

DecisionQ is a leader in predictive analytics and machine learning technologies with expertise in the healthcare, life sciences, financial services and security industries. Through the application of its advanced technologies and methods it delivers customers substantial improvements in the speed and quality of decision making by allowing them to quickly turn data into actionable insights. To learn more about DecisionQ visit

                                         Laura Phillips, Vehr Communications

SOURCE DecisionQ Corporation
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. E&K Scientific Announces Partnership with Sciformatix
2. PRA International Presents Key Budgeting Strategies at 18th Annual CRO Partnerships Conference
3. Isis and Partners Present New Research at the American Association for Cancer Research 2009 Annual Meeting
4. Brazils top automakers to distribute 2 million copies of the Ethanol Handbook in partnership with the Brazilian Sugarcane Industry Association
5. Childrens Memorial Research Center, Chicago Becomes a Member of GeneGos MetaMiner Stem Cell Partnership Program
6. ViewRay Incorporated Closes $15M Tranche of Series B Financing and Announces Partnership with Siemens AG
7. US Oncology Clinical Development Attends Partnerships With CROs
8. Aviation partners to cut 500,000 tonnes of CO2 a year
9. ChemImage and Next Breath Structure Partnership to Validate Bioequivalence Testing for Nasal Spray Suspensions
10. ACM Global Central Lab Announces Partnership with Chindexs United Family Hospitals in China
11. Van Andel Institute Joins the MetaMiner Oncology Partnership Program
Post Your Comments:
(Date:11/25/2015)... India , November 26, 2015 ... The Global Biobanking Market 2016 - 2020 report ... by maintaining integrity and quality in long-term samples, ... enabling long-term cost-effectiveness. Automation minimizes manual errors such ... the technical efficiency. Further, it plays a vital ...
(Date:11/25/2015)... Nov. 25, 2015  PharmAthene, Inc. (NYSE MKT: PIP) ... a stockholder rights plan (Rights Plan) in an effort ... carryforwards (NOLs) under Section 382 of the Internal Revenue ... PharmAthene,s use of its NOLs could be substantially ... defined in Section 382 of the Code. In general, ...
(Date:11/25/2015)... , November 25, 2015 2 ... première fois les différences entre les souches bactériennes ... celles des êtres humains . Ces recherches ... et envisager la prise en charge efficace de ... diagnostiqués chez les chats .    --> ...
(Date:11/25/2015)... Studies reveal the differences in ... pave the way for more effective treatment for one of ...   --> --> Gum ... in cats, yet relatively little was understood about the bacteria ... been conducted by researchers from the WALTHAM Centre for Pet ...
Breaking Biology Technology:
(Date:11/20/2015)... , November 20, 2015 ... company focused on the growing mobile commerce market and ... Gino Pereira , was recently interviewed on ... will air on this weekend on Bloomberg Europe ... America . --> NXTD ) ("NXT-ID" or ...
(Date:11/19/2015)... , Nov. 19, 2015  Based on its ... & Sullivan recognizes BIO-key with the 2015 Global Frost ... year, Frost & Sullivan presents this award to the ... catering to the needs of the market it serves. ... line meets and expands on customer base demands, the ...
(Date:11/19/2015)... 2015  Although some 350 companies are actively involved ... few companies, according to Kalorama Information. These include Roche Diagnostics, ... market share of the 6.1 billion-dollar molecular testing market, ... for Molecular Diagnostic s .    ... controlled by one company and only a handful of ...
Breaking Biology News(10 mins):